Literature DB >> 10566620

Clinical review 110: Diagnosis and treatment of pituitary tumors.

P U Freda1, S L Wardlaw.   

Abstract

We are fortunate to have multiple safe and effective therapeutic options available for the treatment of pituitary tumors. These options include medical therapy, transsphenoidal surgery and radiotherapy. The treatment of choice depends on the type of pituitary tumor. The majority, of PRL-secreting tumors can be effectively treated with dopamine agonists. Transsphenoidal surgery is also an effective option for patients who are resistant to or intolerant of these drugs. Transsphenoidal surgery remains the treatment of choice for the majority of patients with GH, ACTH, and TSH-secreting tumors and for large nonsecreting tumors. Medical therapy with somatostatin analogs and/or dopamine agonists should be undertaken in patients with persistent elevations of GH and IGF-I levels; radiotherapy should be considered for patients with significant residual tumor in whom medical therapy is unsuccessful. Radiotherapy is also indicated for ACTH-secreting tumors not cured by surgery; medical therapy with ketoconazole and other adrenal enzyme inhibitors can be used as adjunctive therapy to lower cortisol levels. Postoperative radiotherapy for nonsecreting tumors is also an option if there is considerable residual tumor or evidence of tumor growth on follow-up MRI. Evaluation and treatment of hypopituitarism is an important part of the management of all patients with pituitary tumors. Patients also should be monitored for the development of new deficits, particularly after radiotherapy. The development of new medical therapies, such as GH antagonists, as well as refinements of surgical, radiotherapy, and imaging techniques should continue to improve our management of pituitary tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10566620     DOI: 10.1210/jcem.84.11.6202

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

Review 1.  Novel medical approaches for the treatment of Cushing's disease.

Authors:  A P Heaney
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 2.  The pituitary mass: diagnosis and management.

Authors:  Susan Sam; Mark E Molitch
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

3.  A non-functioning pituitary adenoma initially mimicking a microprolactinoma: The case for long-term follow-up of patients with mild hyperprolactinemia?

Authors:  M Losa; P Mortini; M Giovanelli
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

Review 4.  PPAR-gamma in Cushing's disease.

Authors:  Anthony P Heaney
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

5.  Obstructive hydrocephalus and intracranial hypertension caused by a giant macroprolactinoma. Prompt response to medical treatment.

Authors:  Pietro Scarone; Marco Losa; Pietro Mortini; Massimo Giovanelli
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

Review 6.  [Endocrine tumors: clinical overview].

Authors:  G Leidig-Bruckner
Journal:  Radiologe       Date:  2014-10       Impact factor: 0.635

Review 7.  Fluorescence guided surgery for pituitary adenomas.

Authors:  Nikita Lakomkin; Jamie J Van Gompel; Kalmon D Post; Steve S Cho; John Y K Lee; Constantinos G Hadjipanayis
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

8.  Cost-of-illness study in acromegalic patients in Italy.

Authors:  G Didoni; S Grottol; V Gasco; M Battistini; D Ferone; M Giusti; F Ragazzoni; P Ruffo; E Ghigo; F Minuto
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

Review 9.  Pituitary adenomas in childhood.

Authors:  S K Singh; Rohit Aggarwal
Journal:  Indian J Pediatr       Date:  2005-07       Impact factor: 1.967

Review 10.  Novel pituitary ligands: peroxisome proliferator activating receptor-gamma.

Authors:  Anthony P Heaney
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.